[Visceral leishmaniasis related to infliximab administration]

Enferm Infecc Microbiol Clin. 2004 May;22(5):310. doi: 10.1016/s0213-005x(04)73098-0.
[Article in Spanish]
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Antibodies, Monoclonal / adverse effects*
  • Arthritis, Psoriatic / complications
  • Arthritis, Psoriatic / drug therapy*
  • Diabetes Complications
  • Dog Diseases / parasitology
  • Dogs
  • Humans
  • Immunocompromised Host
  • Infliximab
  • Leishmaniasis, Visceral / etiology*
  • Leishmaniasis, Visceral / transmission
  • Leishmaniasis, Visceral / veterinary
  • Male
  • Middle Aged
  • Opportunistic Infections / etiology*
  • Opportunistic Infections / parasitology
  • Opportunistic Infections / transmission

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Infliximab